KAMES CAPITAL plc trimmed its position in Clorox Co (NYSE:CLX) by 67.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 147,592 shares of the company’s stock after selling 304,107 shares during the quarter. KAMES CAPITAL plc’s holdings in Clorox were worth $21,953,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Sun Life Financial INC boosted its holdings in Clorox by 10,344.4% in the 2nd quarter. Sun Life Financial INC now owns 940 shares of the company’s stock worth $125,000 after buying an additional 931 shares during the last quarter. Acrospire Investment Management LLC acquired a new position in shares of Clorox during the 2nd quarter worth approximately $133,000. Phocas Financial Corp. acquired a new position in shares of Clorox during the 2nd quarter worth approximately $167,000. Salem Investment Counselors Inc. boosted its holdings in shares of Clorox by 2.5% during the 2nd quarter. Salem Investment Counselors Inc. now owns 1,256 shares of the company’s stock worth $167,000 after purchasing an additional 31 shares during the last quarter. Finally, Private Asset Management Inc. acquired a new position in shares of Clorox during the 4th quarter worth approximately $208,000. Institutional investors own 73.14% of the company’s stock.
Several research analysts have recently weighed in on CLX shares. Jefferies Group restated a “hold” rating and set a $132.00 target price on shares of Clorox in a report on Wednesday, November 1st. Zacks Investment Research cut Clorox from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Morgan Stanley lowered their target price on Clorox from $138.00 to $128.00 and set an “equal weight” rating on the stock in a report on Thursday, November 2nd. Wells Fargo & Co boosted their target price on Clorox from $130.00 to $146.00 and gave the stock a “market perform” rating in a report on Thursday, January 4th. Finally, Royal Bank of Canada restated a “hold” rating and set a $115.00 target price on shares of Clorox in a report on Sunday, October 8th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $134.33.
Clorox Co (NYSE:CLX) traded down $2.44 during mid-day trading on Friday, hitting $141.99. 1,192,200 shares of the stock traded hands, compared to its average volume of 804,188. The stock has a market cap of $18,240.00, a price-to-earnings ratio of 26.05, a PEG ratio of 3.84 and a beta of 0.42. The company has a current ratio of 1.10, a quick ratio of 0.77 and a debt-to-equity ratio of 3.02. Clorox Co has a 1 year low of $118.41 and a 1 year high of $150.40.
Clorox (NYSE:CLX) last released its quarterly earnings results on Wednesday, November 1st. The company reported $1.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.41 by $0.05. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.48 billion. Clorox had a net margin of 11.84% and a return on equity of 161.59%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.36 EPS. sell-side analysts forecast that Clorox Co will post 5.66 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Wednesday, January 24th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.37%. The ex-dividend date is Tuesday, January 23rd. Clorox’s payout ratio is presently 61.65%.
In other news, SVP Michael R. Costello sold 10,574 shares of Clorox stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the sale, the senior vice president now owns 34,867 shares of the company’s stock, valued at approximately $4,742,260.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Matthew T. Laszlo sold 20,051 shares of Clorox stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $130.46, for a total transaction of $2,615,853.46. Following the sale, the senior vice president now directly owns 10,896 shares in the company, valued at approximately $1,421,492.16. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by insiders.
The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.